

17th DSANJ Bio Conference 2025

Applications accepted Oct. 20–Nov. 20, 2025

Details

| | |
|---------------------------------|--|
| Purpose of this project: | Promoting collaboration on drug discovery, including joint research, technology transfer, fundraising for a startup, etc. |
| One-on-one meetings: | 10:00–18:00 on Jan. 28, 29, 30; Feb. 2, 3, 2026 (choose your own meeting dates and times within this period) |
| Location: | Online (Zoom meetings©) |
| Organizers: | Osaka Chamber of Commerce and Industry (OCCI), Japan Agency for Medical Research and Development (AMED), Japan Pharmaceutical Manufacturers Association (JPMA), Kansai Pharmaceutical Industries Association |
| Co-organizer: | Osaka Prefecture |
| Support: | Japan External Trade Organization (JETRO), Osaka City |
| Participants: | Approx. 80 researchers from universities, research institutions, startups, etc. / Approx. 40 pharmaceutical companies and venture capital |

We're looking for research focused on...

Categories

Drug targets; drug seeds (substances); platform technologies for drug discovery; biomarkers; diagnostic drugs and technologies; digital therapeutics; medical devices for use combination with drugs, etc. (i.e., excluding devices designed for use on their own)

Modalities

Low-molecular drugs, antibody drugs, oligonucleotide therapeutics, gene therapy, recombinant protein, cell therapy, AI-powered drug discovery, vaccines, viruses, regenerative medicine, SaMD (treatment apps), digital healthcare, protein-protein interaction inhibitors, etc.

Target Disorders

Metabolic disorders, circulatory disorders, infectious disorders, respiratory disorders, musculoskeletal disorders, cancer and malignant neoplasms, central nervous system diseases, pain, sensory organ disorders, immune system and inflammatory disorders, allergies, skin disorders, digestive and urinary disorders, ob-gyn disorders, rare disorders, etc.

Stage of Research Progress

Basic research; non-clinical POC pending; non-clinical POC obtained, clinical trials pending; clinical trials underway, etc.

Why you should apply for DSANJ Bio Conference

Support to help you forge partnerships with pharma companies

DSANJ coordinates one-on-one meetings between you and pharmaceutical companies' R&D staff.

Opportunities to see and interact with private-sector drug discovery research

One-on-one meetings with pharmaceutical companies are an excellent chance to learn about the latest thinking in private-sector R&D. Past participants say that information and views heard from corporate researchers are useful for guiding their own basic research.

Schedule

Application Period

Oct. 6–Nov. 6, 2025

Pharma companies' R&D teams read proposal materials and discuss who (if any) they want to meet. Notice of application results and meeting request numbers (if successful) go out around **December 26, 2025**.

Successful applicants invited to participate in DSANJ Bio Conference 2025

One-on-one online meetings with companies looking to invest in new drug R&D: **Jan. 28, 29, 30; Feb. 2, 3, 2026**

Invitations to subsequent conferences

Your information is shown only to participating companies

We notify you of pharma companies' decisions and feedback approx. 1 month after the conference (around Mar. 9)

How to Apply

Apply through the online application page at <https://www.osaka.cci.or.jp/dsanj/researchers/20250519.html>



Ask your institution's partnerships team or intellectual property division, or contact the DSANJ Admin Office